Gynecological

Most recent

OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

NE Oncology Issue - September 2011 Background Results from the OCEANS trial build on findings from two previous phase III studies in newly diagnosed ovarian cancer, GOG 0218 and ICON7.1,2 Both of these studies showed that front-line bevacizumab in combination with...

Twitter feed

Local #radiotherapy improves OS in metastatic #prostatecancer with low disease burden. #ESMO18 https://t.co/RCbjG89hYS
h J R
#Immunotherapy as first-line treatment in some metastatic #colorectal #cancers? #ESMO18 https://t.co/Pl4prgsFo0
h J R
Genetic marker of #pancreaticcancer may predict #radiation therapy outcomes. https://t.co/RIjInoqOmD
h J R
A shortcut to #cancer drug development: live tumour testing. https://t.co/dYZmtRqMhX
h J R
New #cancer #vaccine shows early promise for patients with #HER2-positive cancers. https://t.co/kjLaFxdsbJ
h J R